CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Johnson & Johnson is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Johnson & Johnson
One Johnson & Johnson Plz
Phone: (732) 524-2455p:732 524-2455 NEW BRUNSWICK, NJ  08933  United States Ticker: JNJJNJ
Business Summary
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/29/202412/31/2023YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
3841 Surgical and medical instruments and apparatus
3845 Electromedical and electrotherapeutic apparatus
3851 Ophthalmic goods
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research
7372 Prepackaged software
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Joaquin B.Duato 61 1/1/2023 4/1/2016
Chief Financial Officer, Executive Vice President Joseph J.Wolk 57 12/1/2018 7/1/2018
Chief Human Resource Officer KristenMulholland 10/1/2024 10/1/2024
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AMO AUSTRALIA PTY LTD
AMO SINGAPORE PTE LIMITED
AMO SWITZERLAND GMBH
215 additional Subsidiary records available in full report.

Business Names
Business Name
ABD Holding Company, Inc.
ABIOMED AUSTRALIA PTY LTD
ABIOMED COMMERCIAL, LLC
412 additional Business Names available in full report.

General Information
Number of Employees: 131,900 (As of 12/31/2023)
Outstanding Shares: 2,407,622,972 (As of 10/16/2024)
Shareholders: 118,772
Stock Exchange: NYSE
Federal Tax Id: 221024240
Fax Number: (732) 214-0332


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024